Filters: Author is Barlow, William E [Clear All Filters]
Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.. Patient education and counseling. 91(3):364-71.. 2013.
Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age.. Cancer research. 74(15):4078-89.. 2014.
Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 23(5):755-64.. 2014.
Does surgeon case volume influence nonfatal adverse outcomes after rectal cancer resection? Journal of the American College of Surgeons. 206(3):1167-77.. 2008.
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(1):58-64.. 2015.
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5.. 2008.
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(27):4449-57.. 2008.
A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102.. Breast cancer research and treatment. 143(2):351-8.. 2014.
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47.. 2010.
Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up.. Journal of the National Cancer Institute.. 2014.
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.. British journal of clinical pharmacology.. 2016.
Measuring the performance of markers for guiding treatment decisions.. Annals of internal medicine. 154(4):253-9.. 2011.
Combination anastrozole and fulvestrant in metastatic breast cancer.. The New England journal of medicine. 367(5):435-44.. 2012.
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.. The New England journal of medicine. 372(10):923-32.. 2015.
Contrasting two frameworks for ROC analysis of ordinal ratings.. Medical decision making : an international journal of the Society for Medical Decision Making. 30(4):484-98.. 2010.
Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.. Cancer causes & control : CCC. 22(3):399-405.. 2011.
Breast Density, Body Mass Index, and Risk of Tumor Marker-Defined Subtypes of Breast Cancer.. Annals of epidemiology. 22(5):340-348.. 2012.
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.. Breast cancer research and treatment. 126(3):671-8.. 2011.
Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(6):1643-54.. 2010.
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy.. Breast cancer research and treatment.. 2014.
Doing Business with Arnold Library
Weintraub Building, B1-010
More About Arnold Library
- Journals List
- Ovid (guest or library account)
- Web of Science - Science Citation Index
- Pubmed (Get Article Enabled)
- Library Catalog (Account Login)
- Document Delivery Form
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Authored Papers (Intranet)